Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.

Basit Öğe Kaydı
dc.authoridUcar, Gokhan/0000-0002-7649-1075
dc.authoridGökyer, Ali/0000-0002-1653-6155
dc.authoridPaydas, Semra/0000-0003-4642-3693
dc.authoridBuyuksimsek, Mahmut/0000-0001-6356-9059
dc.authoridSimsek, Melih/0000-0003-0633-8558
dc.authoridKEFELI, UMUT/0000-0001-6126-5377
dc.authorwosidUcar, Gokhan/AAA-8198-2021
dc.authorwosidGökyer, Ali/AAQ-5700-2020
dc.authorwosidUygun, Kazim/AAG-7880-2022
dc.authorwosidGunaydin, Ulug/AAD-6634-2020
dc.authorwosidPaydas, Semra/F-3132-2018
dc.authorwosidBuyuksimsek, Mahmut/R-3412-2018
dc.authorwosidUygun, Kazim/AFL-7917-2022
dc.contributor.authorIsik, Ulas
dc.contributor.authorKostek, Osman
dc.contributor.authorDemiray, Gokcen
dc.contributor.authorDirican, Ahmet
dc.contributor.authorSimsek, Melih
dc.contributor.authorBuyuksimsek, Mahmut
dc.contributor.authorUcar, Gokhan
dc.date.accessioned2024-06-12T11:22:27Z
dc.date.available2024-06-12T11:22:27Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2019 -- Chicago, ILen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.e16075
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue15en_US
dc.identifier.urihttps://doi.org/10.1200/JCO.2019.37.15_suppl.e16075
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25939
dc.identifier.volume37en_US
dc.identifier.wosWOS:000487345801503en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAmer Soc Clinical Oncologyen_US
dc.relation.ispartofJournal Of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleReal life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu